Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) reported results from a Health Trends study with Hologic analyzing deidentified molecular test data from over 1.5 million U.S. women (2022–2024), published in O&G Open. Overall, 38.7% tested positive for bacterial vaginosis (BV) and 28.5% for vulvovaginal candidiasis; 10.8% had both.
Among BV‑positive women, 12.0% had at least one non‑viral STI versus 3.8% of BV‑negative women. After adjustment, BV positivity was associated with higher odds of chlamydia (2.8x), gonorrhea (3.8x), trichomonas (3.6x) and Mycoplasma genitalium (1.9x). Candidiasis alone was not associated with increased STI risk. Quest noted the large, nationally representative sample as a strength, and single‑lab, limited patient data as key limitations, and highlighted its 2024 rollout of self‑collection services for BV and related infections.
Quest Diagnostics (NYSE: DGX) reported second quarter 2026 net revenues of $3.04 billion, up 10.2% year over year, driven by 10.0% organic revenue growth and a 13.1% increase in requisition volume. Diagnostic Information Services revenues rose 10.3%.
Reported diluted EPS was $2.84, up 15.0%, while adjusted diluted EPS was $3.12, up 19.1%. Operating cash flow for the quarter was $597 million, up 9.7%. The company raised its 2026 guidance, now expecting net revenues of $11.95–$12.05 billion, reported diluted EPS of $9.97–$10.17, and adjusted diluted EPS of $11.05–$11.25. Expected 2026 cash from operations was increased to approximately $1.80 billion, with capital expenditures unchanged at about $550 million.
Quest Diagnostics (NYSE:DGX) reported that 19.1% of general U.S. workers tested via hair in 2025 were drug-positive, up from 13.1% in 2021, according to its 2026 Drug Testing Index. Marijuana hair positivity reached 15.1%, a 58.9% increase over five years and 52.5% of all hair positives.
Overall urine drug positivity in the workforce was 4.3% in 2025, slightly below 4.4% in 2024 but above 4% for more than a decade. Marijuana positivity was 4.4% in urine, 11.1% in oral fluid, and 15.1% in hair. Healthcare showed the highest industry positivity at 5.8%, with retail trade and professional and technical services also elevated. Fentanyl positivity in the general workforce declined 49.1% year over year, from 0.55% in 2024 to 0.28% in 2025.
Quest Diagnostics (NYSE: DGX) is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling for solid tumors into Flatiron Health's OncoEMR MPI via a pilot with American Oncology Network and other community practices.
The integration aims to simplify molecular test ordering and results for up to 4,700 clinicians across 1,600 cancer care locations nationwide in the second half of the year.
Quest Diagnostics (NYSE:DGX) received New York State Department of Health CLEP approval for its Haystack MRD ctDNA liquid biopsy test to identify residual or recurring disease in a range of solid tumor cancers.
With this authorization, Haystack MRD is now available for patient testing in all 50 U.S. states, supported by published clinical data showing it identified clinical complete response at a median of 1.4 months versus over 6 months with imaging.
Quest Diagnostics (NYSE:DGX) and Hackensack Meridian CDI reported a nationwide study in Nature Communications on multidrug-resistant Klebsiella pneumoniae causing community urinary tract, pneumonia and wound infections.
The study analyzed 2,000+ U.S. samples, finding 100% multidrug resistance and 69.5% non-susceptibility to three leading oral UTI antibiotics.
Quest Diagnostics (NYSE: DGX) will release its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. A conference call to discuss the results begins at 8:30 a.m. Eastern Time and will be accessible by phone or webcast.
Replays will be available by phone and online from approximately 10:30 a.m. Eastern Time on July 23, 2026, until midnight Eastern Time on August 6, 2026. Listeners are encouraged to review the company’s SEC filings, including risk factors and historical results.
Quest Diagnostics (NYSE:DGX) released its 2025 Corporate Responsibility Report, themed “At the Center of Healthcare.” The report reviews progress since 2021 across four pillars: health access, employee and community engagement, governance and ethics, and environmental sustainability.
Highlights include over one million discounted or donated tests worth more than $21 million, improved workforce retention and engagement, enhanced AI and cybersecurity governance, and new ISO 14001:2015 environmental certifications that meet the goal of certifying five laboratories by the end of 2025.
Quest Diagnostics (NYSE: DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share.
The dividend is payable on July 22, 2026 to shareholders of record as of July 8, 2026.
Quest Diagnostics (NYSE: DGX) priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration. The company expects net proceeds at closing on May 6, 2026, to be used for general corporate purposes, which may include repaying indebtedness.
The announcement notes the company may repay its $500 million aggregate principal amount of 3.45% senior notes maturing on June 1, 2026. The offering will be made via a prospectus supplement and base prospectus; bookrunners include Goldman Sachs, J.P. Morgan, and Mizuho.